Filing Flows › Lifevantage (LFVN) › Q1 2026 › vs Q4 2025
Lifevantage (LFVN) Q1 2026 vs Q4 2025 (quarter over quarter)
Lifevantage's revenue fell $5.2M (-11%) from $48.9M in Q4 2025 to $43.7M in Q1 2026. The biggest changes: True Science Product Line −$1.2M (-12%); Protandim −$977K (-5%); Life Vantage Product Line −$903K (-13%). Gross margin 79.0% against 74.0% (+5.0 pts).
Lifevantage, Q1 2026: revenue $43.7M (-25% year over year), operating margin 3.8%, net earnings $1.4M, operating cash flow $5.0M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Gross margin | 79.0% | 74.0% | +5.0 pts |
| Operating margin | 3.8% | 1.0% | +2.8 pts |
| Net margin | 3.1% | 0.6% | +2.6 pts |
| Free cash flow margin | 9.1% | 3.5% | +5.6 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Protandim | $20.0M | $20.9M | −$977K | -5% |
| True Science Product Line | $8.9M | $10.1M | −$1.2M | -12% |
| Life Vantage Product Line | $6.3M | $7.2M | −$903K | -13% |
| AXIO Product Line | $3.4M | $3.9M | −$486K | -12% |
| Love Biome Product Line | $3.2M | $4.1M | −$888K | -22% |
| Phys IQ Product Line | $847K | $1.1M | −$203K | -19% |
| Product and Service Other | $632K | $1.2M | −$532K | -46% |
| Petandim Product Line | $466K | $501K | −$35K | -7% |
| Revenue | $43.7M | $48.9M | −$5.2M | -11% |
| Gross profit | $34.5M | $36.2M | −$1.7M | -5% |
| Cost of revenue | $9.2M | $12.7M | −$3.5M | -28% |
| Operating profit | $1.7M | $487K | $1.2M | +245% |
| Operating expenses | $32.9M | $35.7M | −$2.9M | -8% |
| Pre-tax earnings | $1.7M | $473K | $1.2M | +250% |
| Research & development | $200K | $200K | $0 | 0% |
| SG&A | $13.9M | $15.8M | −$2.0M | -12% |
| Other operating costs | $18.8M | $19.7M | −$894K | -5% |
| Net earnings | $1.4M | $276K | $1.1M | +393% |
| Income tax | $294K | $197K | $97K | +49% |
| Depreciation & amortization | $714K | $752K | −$38K | -5% |
| Share-based compensation | $704K | $553K | $151K | +27% |
| Working capital & other | $2.2M | $1.2M | $998K | +82% |
| Operating cash flow | $5.0M | $2.8M | $2.2M | +79% |
| Free cash flow (OCF − capex) | $4.0M | $1.7M | $2.3M | +133% |
| Capital expenditures | $1.0M | $1.1M | −$73K | -7% |
Questions
How much did Lifevantage's revenue grow quarter over quarter in Q1 2026?
Lifevantage's revenue fell $5.2M (-11%) from $48.9M in Q4 2025 to $43.7M in Q1 2026.
What drove Lifevantage's revenue change in Q1 2026?
True Science Product Line −$1.2M (-12%); Protandim −$977K (-5%); Life Vantage Product Line −$903K (-13%).